1-4 of 4
James F. Spicer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Free
David S. Hong, Nicole Concin, Ignace Vergote, Johann S. de Bono, Brian M. Slomovitz, Yvette Drew, Hendrik-Tobias Arkenau, Jean-Pascal Machiels, James F. Spicer, Robert Jones, Martin D. Forster, Nathalie Cornez, Christine Gennigens, Melissa L. Johnson, Fiona C. Thistlethwaite, Reshma A. Rangwala, Srinivas Ghatta, Kristian Windfeld, Jeffrey R. Harris, Ulrik Niels Lassen, Robert L. Coleman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (6): 1220–1228.
https://doi.org/10.1158/1078-0432.CCR-19-2962
Published: 13 March 2020
View article titled, Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
Open the PDF for Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer in another window
Includes: Supplementary data
Journal Articles

Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer

Free
Anthony Cheung, James Opzoomer, Kristina M. Ilieva, Patrycja Gazinska, Ricarda M. Hoffmann, Hasan Mirza, Rebecca Marlow, Erika Francesch-Domenech, Matthew Fittall, Diana Dominguez Rodriguez, Angela Clifford, Luned Badder, Nirmesh Patel, Silvia Mele, Giulia Pellizzari, Heather J. Bax, Silvia Crescioli, Gyula Petranyi, Daniel Larcombe-Young, Debra H. Josephs, Silvana Canevari, Mariangela Figini, Sarah Pinder, Frank O. Nestle, Cheryl Gillett, James F. Spicer, Anita Grigoriadis, Andrew N.J. Tutt, Sophia N. Karagiannis
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (20): 5098–5111.
https://doi.org/10.1158/1078-0432.CCR-18-0652
Published: 15 October 2018
View article titled, Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer
Open the PDF for Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer

Free
Tamara Muliaditan, James W. Opzoomer, Jonathan Caron, Mary Okesola, Paris Kosti, Sharanpreet Lall, Mieke Van Hemelrijck, Francesco Dazzi, Andrew Tutt, Anita Grigoriadis, Cheryl E. Gillett, Stephen F. Madden, Joy M. Burchell, Shahram Kordasti, Sandra S. Diebold, James F. Spicer, James N. Arnold
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (7): 1617–1628.
https://doi.org/10.1158/1078-0432.CCR-17-2587
Published: 02 April 2018
View article titled, Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer
Open the PDF for Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase 1 Study of AS1409, a Novel Antibody-Cytokine Fusion Protein, in Patients with Malignant Melanoma or Renal Cell Carcinoma

Free
Sarah M. Rudman, Michael B. Jameson, Mark J. McKeage, Philip Savage, Duncan I. Jodrell, Mark Harries, Gary Acton, Fredrik Erlandsson, James F. Spicer
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (7): 1998–2005.
https://doi.org/10.1158/1078-0432.CCR-10-2490
Published: 31 March 2011
View article titled, A Phase 1 Study of AS1409, a Novel Antibody-Cytokine Fusion Protein, in Patients with Malignant Melanoma or Renal Cell Carcinoma
Open the PDF for A Phase 1 Study of AS1409, a Novel Antibody-Cytokine Fusion Protein, in Patients with Malignant Melanoma or Renal Cell Carcinoma in another window